News
Study: Weight Loss Drugs Can Cut Risk Of Death Or Hospitalization For Heart Patients by Half
|By
Belaaz HQ2 MIN READ
Published Aug. 31, 2025, 11:51 AM
News

A major international study released Sunday has found that popular weight loss drugs can cut in half the risk of heart patients being hospitalized or dying prematurely, marking the largest and most significant research yet into their benefits beyond obesity.
The medications, known as GLP-1 agonists, were originally designed for diabetes treatment but mimic the GLP-1 hormone that induces a feeling of fullness. Researchers presented the findings at the European Society of Cardiology’s annual meeting in Madrid, saying the drugs deliver “dramatic benefits” for heart patients.
The data showed that semaglutide reduced the combined risk of hospitalization or early death by 42%, while tirzepatide achieved a 58% reduction. The study, published simultaneously in the Journal of the American Medical Association (JAMA), analyzed health records of more than 90,000 obese patients with type 2 diabetes who also suffered from heart failure with preserved ejection fraction (HFpEF), the most common type of heart failure.
Dr. Nils Krüger of Brigham and Women’s Hospital, one of the study authors, noted that current treatments for HFpEF are limited. He said, “Both semaglutide and tirzepatide are well known for their effects on weight loss and blood sugar control, but our study suggests they may also offer substantial benefits to patients with obesity and type 2 diabetes by reducing adverse heart failure outcomes.”
Globally, more than 60 million people live with heart failure. Earlier research hinted that weight loss injections could ease symptoms, but this is the first large-scale study to show meaningful reductions in hospitalizations and death rates.
Independent experts welcomed the results but urged caution. Dr. Carlos Aguiar, vice-president of the European Society of Cardiology, said, “What this shows is that there is a benefit in using one of these two agents, semaglutide or tirzepatide, to reduce the risk of hospitalisation for heart failure or all-cause mortality.” He added that while the findings are encouraging, more evidence is needed before doctors widely prescribe the drugs for heart failure patients.
The results follow a University College London study in May that showed semaglutide lowered the risk of heart attack, stroke, or cardiovascular death by 20%, regardless of a patient’s weight.
Dr. Sonya Babu-Narayan of the British Heart Foundation said the new findings “add to the growing body of evidence supporting a role for weight loss drugs for patients living with both heart failure and obesity, to reduce hospital admissions and death,” emphasizing the importance of ensuring eligible patients have access to these therapies.
MOST READ



